Key result
Study outlines design to evaluate cardiometabolic polygenic risk scores and APOE alleles for dementia risk.
Why the study?
Cardiometabolic diseases and their risk factors predict dementia, but how genetic predictors of cardiometabolic diseases influence dementia-related outcomes remains unclear.
Do polygenic risk scores for major cardiometabolic diseases and APOE risk alleles influence dementia-related outcomes in a diverse population?
Cohort
Yes
Do polygenic risk scores for major cardiometabolic diseases and APOE risk alleles influence dementia-related outcomes in a diverse population?
This study aims to clarify how genetic predictors of cardiometabolic diseases and APOE risk alleles influence dementia-related outcomes in a diverse cohort.
May inform dementia risk in diverse cohorts; leaves open quantitative validation of associations.
Late-life dementia has a strong heritable component. While the APOE ɛ4 allele is the strongest genetic risk factor of Alzheimer disease (AD), polygenic risk factors also play a significant role. Cardiometabolic diseases (CMDs) and their risk factors predict dementia in many cohorts, but how genetic predictors of CMD influence dementia-related outcomes remains unclear. In this study, we examined the associations of polygenic risk scores (PRSs) for major CMDs and the established APOE risk alleles with dementia-related outcomes in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study, which is enriched for Black participants underrepresented in late-life dementia research.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2026) conducted a cohort in Late-life dementia. Polygenic risk scores (PRSs) for major cardiometabolic diseases and APOE risk alleles was evaluated on Dementia-related outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: